**Title:** Major Indian Pharma Companies Recall Drugs in the US Market
**Meta Description:** Sun Pharma, Lupin, and Dr. Reddy’s Laboratories are recalling medications in the US due to manufacturing issues and product mix-ups.
**URL Slug:** indian-pharma-recalls-us-market
**Headline:** Indian Pharmaceutical Giants Recall Medications in the US Due to Manufacturing Concerns
In a significant development, leading Indian pharmaceutical companies Sun Pharma, Lupin, and Dr. Reddy’s Laboratories are recalling several medications from the US market due to manufacturing discrepancies and product mix-ups, as reported by the US Food and Drug Administration (FDA).
Sun Pharmaceutical Industries, based in Mumbai, is recalling 5,448 bottles of a generic medication, Lisdexamfetamine Dimesylate capsules, which are commonly prescribed for attention deficit hyperactivity disorder (ADHD). The recall was initiated on June 16, 2023, due to “Failed Dissolution Specifications,” indicating that the product did not meet the required standards for release of the active ingredient.
Similarly, Lupin Pharmaceuticals, also headquartered in Mumbai, is recalling 58,968 bottles of a combination medication used to manage high blood pressure. The affected lot of Lisinopril and Hydrochlorothiazide tablets was produced at the company’s manufacturing facility in Nagpur. The recall, initiated on June 20, 2023, was prompted by a complaint regarding a mix-up where a sealed bottle contained foreign tablets identified as Atazanavir and Ritonavir, which are not part of the intended product.
In another instance, Dr. Reddy’s Laboratories is recalling 1,476 bottles of Omeprazole Delayed-release capsules, which are utilized for treating certain stomach and esophagus conditions. This recall, initiated on June 30, 2023, was due to the presence of foreign Divalproex Sodium extended-release tablets found in the bottles of Omeprazole capsules. The affected products were manufactured at the company’s facility in Bachupally.
The FDA classifies these recalls as Class II, indicating that the use or exposure to the violative products may lead to temporary or medically reversible health consequences, with minimal likelihood of serious adverse health outcomes.
As these recalls unfold, it highlights the importance of stringent manufacturing practices and quality control in the pharmaceutical industry to ensure patient safety.
**FAQ Section:**
**Q: What is a Class II recall?**
A: A Class II recall is issued when a product may cause temporary or reversible health issues, or when the risk of serious health consequences is minimal.
